Ocugen, Inc. (OCGN) Q1 2021 Earnings Call Transcript : vimar

Ocugen, Inc. (OCGN) Q1 2021 Earnings Call Transcript


Operator
Good morning and welcome to the Ocugen conference call. At this time, all participants are in listen-only mode. [Operator instructions] Please note this conference is being recorded. I would now like to turn the conference over to Lisa DeScenza, vice president of integrated communications at LaVoie Health Science to introduce the Ocugen team.
You may begin.
Vice President of Integrated Communications
Thank you, operator. I'd like to welcome you to our conference call. With me today are Ocugen's chairman and CEO, Dr. Shankar Musunuri, and our CFO and head of corporate development, Sanjay Subramanian.
Earlier this morning Ocugen issued a press release, including a business update and first-quarter 2021 financial results. We encourage listeners to review the press release, which is available on the Ocugen website at www.ocugen.com. This call is also being recorded and a replay will be available on the Investor section of the Ocugen website for approximately 45 days. Before we begin our formal comments, I'll remind you that various remarks we make today constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties.

Related Keywords

India , United States , Brazil , Brazilian , Bharat , Sanjay Subramanian , Shankar Musunuri , Keay Nakae , Anthony Fauci , Keay Nakae Chardan , Lisa Descenza , Lavoie Health Science , Biomedical Advanced Research , World Health Organization , Drug Administration , Development Authority , Ocugen Inc , Exchange Commission , Head Of Corporate Development , Association For Research , Private Securities Litigation Reform Act , Bharat Biotech , Risk Factors , Chief Executive , Financial Officer , இந்தியா , ஒன்றுபட்டது மாநிலங்களில் , பிரேசில் , பிரேசிலியன் , பாரத் , சஞ்சய் சுப்ரமணியன் , லிசா சேசென்ச , லாவோய் ஆரோக்கியம் அறிவியல் , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , வளர்ச்சி அதிகாரம் , பரிமாற்றம் தரகு , தலை ஆஃப் பெருநிறுவன வளர்ச்சி , சங்கம் க்கு ஆராய்ச்சி , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , பாரத் பயோடெக் , ஆபத்து காரணிகள் , தலைமை நிர்வாகி , நிதி அதிகாரி ,

© 2025 Vimarsana